HC Wainwright Reiterates “Buy” Rating for Chimerix (NASDAQ:CMRX)

HC Wainwright restated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research report report published on Monday,Benzinga reports. The brokerage currently has a $11.00 target price on the biopharmaceutical company’s stock.

Separately, Wedbush restated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Stock Down 0.6 %

NASDAQ:CMRX opened at $3.44 on Monday. Chimerix has a 52 week low of $0.75 and a 52 week high of $3.66. The company has a fifty day simple moving average of $1.50 and a two-hundred day simple moving average of $1.11. The company has a market cap of $309.38 million, a price-to-earnings ratio of -3.66 and a beta of 1.02.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently modified their holdings of the company. Valeo Financial Advisors LLC increased its holdings in Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 69,505 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Chimerix in the 2nd quarter valued at about $137,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 138,098 shares in the last quarter. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.